Which SVT drug do patients prefer? small study aims to find out
NCT ID NCT07086560
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at two common emergency room drugs for a fast heart condition called SVT: adenosine and diltiazem. Adenosine can cause scary side effects like a feeling of doom, while diltiazem may lower blood pressure. Researchers will review medical records and ask 20 patients about their satisfaction with the treatment they received. The goal is to understand which drug patients prefer and how safe each one is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adenosine and diltiazem
- What this could lead to
- If successful, this study could help doctors choose the SVT treatment that patients prefer and tolerate better.
- What could go wrong
- This is a small, observational study (20 people) that looks back at past treatments, so it cannot prove one drug is better. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUPRAVENTRICULAR TACHYCARDIA (SVT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Iowa Health Care
RECRUITINGIowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.